The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...

Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.

Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction, ...

U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease ...

Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

Today, a brief rundown of news involving Arcus Biosciences and Eli Lilly, as well as updates from TriGemX Bio and AstraZeneca that you may have missed. Eli Lilly is teaming up with Hong Kong-based ...

An experimental pill from Boston-based Rapport Therapeutics narrowly succeeded in a mid-stage study focused on bipolar mania, an outcome that analysts described as unexpected and a potential stepping ...

The launch prices of two-thirds of the new prescription drugs reviewed by the watchdog group ICER between 2022 and 2025 far exceeded the organization’s threshold of cost-effectiveness, according to a ...

Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 ...